Introduction {#Sec1}
============

The number of elderly individuals suffering from type 2 diabetes (T2DM) is continuously growing worldwide. This is related to the overall aging of the population as well as to a continuous increase in the prevalence of T2DM with age, reaching about 20% in adults aged 75 years or older \[[@CR1]\]. These elderly patients have an increased prevalence of T2DM-related morbidity and mortality, physical disability and frailty, cognitive disorders and, in particular, micro- and macrovascular co-morbidities, such as congestive heart failure and renal impairment (RI) \[[@CR2]\].

Diabetes is the leading causes of chronic kidney disease \[[@CR3]\], with T2DM patients accounting for about 1/3 of all cases of end stage renal disease (ESRD) requiring dialysis \[[@CR4]\]. In addition, there is also an age-related decline in kidney function \[[@CR5]\]. Ultimately, between 25% and 40% of patients with T2DM will develop RI \[[@CR6]\]. In a large-scale French survey, for example, 28% of the population of patients with T2DM ≥65 years had moderate RI and this increased to 37% for patients aged 75--79 years \[[@CR7]\].

The elderly population with T2DM and moderate or severe RI is a uniquely fragile population and effective treatment in this vulnerable population poses special challenges. These include a high prevalence of polypharmacy, which increases the risk of drug--drug interactions, presence of multiple co-morbidities, and the paucity of clinical data in this population. Importantly, treatment options are more limited and/or complex in this population due to contraindications, differential clearance and/or metabolism of anti-hyperglycemic agents, need for dose adjustment and/or regular monitoring. In addition, there is a higher risk for side effects, in particular, a high susceptibility and dangerousness of hypoglycemia. The risk of hypoglycemia associated with drug treatment (insulin secretagogues and insulin) increases markedly with age \[[@CR2], [@CR8]\] and hypoglycemia in the elderly is associated with more severe consequences and complications \[[@CR2]\]. The risk of adverse effects is further increased by a marked unawareness of hypoglycemia in the elderly population, leading to more frequent and severe events \[[@CR9], [@CR10]\]. Furthermore, RI is also associated with an increased incidence of hypoglycemia due to decreased renal neoglycogenesis \[[@CR11]\]. For example, in a retrospective cohort analysis, the incidence of hypoglycemia (glucose \<70 mg/dL) was 10.72 events per 100 patient-months in diabetic patients with chronic kidney disease versus 5.33 in those without chronic kidney disease \[[@CR12]\]. Additionally, RI is associated with differential clearance and/or metabolism of several anti-hyperglycemic agents; in particular, consequent overexposure to insulin secretagogues is often linked to an increased risk of hypoglycemia \[[@CR13]\]. Similarly, the difficulty with insulin dose selection due to impaired catabolism and clearance of exogenous insulin in patients with RI further increases the risk of hypoglycemia \[[@CR13]\].

Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4) that extends the meal-induced increases in the levels of the incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving the sensitivity and responsiveness of pancreatic α-cells and β-cells to glucose \[[@CR14]\]. This results in glucose-sensitive modulation of insulin and glucagon secretion, improving both fasting and postprandial glycemic control, with a low risk of hypoglycemia \[[@CR14]\]. A hypoglycemia risk similar to placebo has consistently been seen with vildagliptin across a wide spectrum of patients/disease \[[@CR15]\], including elderly patients \[[@CR2], [@CR16]\], patients with RI \[[@CR17]--[@CR19]\] and/or patients treated with insulin \[[@CR20]\]. This included data from a dedicated 24-week study of vildagliptin 50 mg qd in patients with moderate or severe RI \[[@CR17]\]. In this large study \~20% of patients were 75 years or older, which provided an opportunity to assess the efficacy and tolerability of vildagliptin in this particularly vulnerable and difficult-to-treat elderly T2DM patient population with RI. Accordingly, the authors report here the experience with vildagliptin in patients ≥75 years with T2DM and moderate/severe RI based on a sub-analysis of the afore-mentioned study \[[@CR17]\].

Materials and Methods {#Sec2}
=====================

Patients and Study Design {#Sec3}
-------------------------

This was a post hoc sub-analysis of data from a previously described \[[@CR17]\] multi-center, randomized, double-blind, parallel-group, 24-week study that assessed safety and efficacy of vildagliptin (50 mg qd) versus placebo in 515 patients with T2DM and moderate (*n* = 294) or severe (*n* = 221) RI. The key entry criteria for this trial included age of 18--85 years, body mass index (BMI) of 18--42 kg/m^2^, glycated hemoglobin (HbA~1c~) of 6.5--10% and T2DM either untreated or treated with a sulfonylurea (SU), alpha-glucosidase inhibitor (AGI), thiazolidinedione (TZD), insulin, meglitinide or a combination of agents provided that doses were stable for at least 4 weeks before the first study visit. Patients also had to continue their current diet/exercise regimen and background therapy unchanged throughout the duration of the study. The diet or caloric intake was not specifically monitored during the study. Addition or intensification of insulin therapy was defined as initiating rescue medication. After a 2-week single-blind, placebo run-in period, eligible patients were randomized (baseline, BL) to vildagliptin (50 mg qd, *n* = 289) or placebo (*n* = 226). The detailed design of this study was described previously \[[@CR17]\].

The data analysis presented here includes only patients with age ≥75 years, resulting in 105 patients with moderate or severe RI \[estimated glomerular filtration rate (eGFR) ≥30 to \<50 ml/min/1.73 m^2^ and \<30 ml/min/1.73 m^2^, respectively\] contributing to the sub-analysis.

Study Assessments {#Sec4}
-----------------

HbA~1c~, fasting plasma glucose (FPG), and weight were regularly assessed at 4-week intervals. The laboratory assessments were performed by a central laboratory \[Covance (Geneva, Switzerland, Singapore, or Indianapolis, IN, USA)\]. Responder analysis was also performed as described below.

Hypoglycemia was defined as symptoms suggestive of low blood glucose confirmed by self-monitored blood glucose (SMBG) measurement \<3.1 mmol/l plasma glucose equivalent. Severe hypoglycemia was defined as any episode requiring assistance of another party (whether or not a confirmatory SMBG measurement was available).

All adverse events (AEs) were recorded and assessed by the investigator for severity and possible relationship to study medication. GFR was estimated by the Modification of Diet in Renal Disease study method (MDRD).

Statistical Analysis {#Sec5}
--------------------

The total number of patients and demographic and clinical characteristics are presented.

The adjusted mean changes (AMΔ) in HbA~1c~, FPG and weight from BL to endpoint \[with final observation carried forward (LOCF)\] were compared between treatments using an analysis of covariance (ANCOVA) model with baseline value, background therapy, pooled center, and treatment as covariates. Data were censored at initiation of rescue medication. Responder rates (percentage of patients with baseline HbA~1c~ ≥7.5% achieving endpoint HbA~1c~ \<7.5%) were assessed by treatment and compared by Fisher's exact test. For hypoglycemia, event rates per patient-year (defined as number of events/total subject year exposure) were compared between treatments with inference based on a normal approximation of the Poisson distribution. In addition, the number of patients experiencing events and the number of events were summarized descriptively. Safety data were summarized descriptively by treatment.

Ethics and Good Clinical Practice {#Sec6}
---------------------------------

The study underlying this sub-analysis was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000 and 2008 and International Conference on Harmonization/Good Clinical Practice guidelines. The study protocol was approved by an independent ethics committee/institutional review board (IRB) at each site and all patients provided written informed consent.

Results {#Sec7}
=======

Demography {#Sec8}
----------

One hundred and five patients \[50 in the vildagliptin (50 mg qd) group and 55 in the placebo group\] with moderate or severe RI and aged 75 years or older at study entry were included in this analysis. Table [1](#Tab1){ref-type="table"} summarizes the demographic and clinical characteristics in the randomized population. These elderly patients with moderate or severe RI had a mean age of 78.1 years and a mean eGFR of 35.3 ml/min/1.73 m^2^. Nearly 1/3 of patients ≥75 years had severe RI and the remaining about 2/3 of patients had moderate RI. The randomized patients had a mean HbA~1c~ of 7.8%, mean FPG of 8.5 mmol/L and mean BMI of 30.5 kg/m^2^, and were treated mainly with either insulin (\~55%) or oral anti-diabetic drug (OAD) monotherapy (\~25%), or a combination of insulin and OAD (\~13%). As expected, patients had long-standing T2DM (mean duration of 16.2 years, with 2/3 of patients being diagnosed with T2DM for ≥10 years), nearly all patients (96.2%) had hypertension and \>2/3 of patients (68.6%) had dyslipidemia. Furthermore, in line with their advanced age and T2DM, more than half of the patients (53.3%) had a high cardiovascular (CV) risk status, defined as previous history of CV and cerebrovascular (CCV) events in the Standard MedDRA Queries (SMQs) of 'ischemic heart disease, cardiac failure, ischemic cerebrovascular conditions and/or embolic/thrombotic events arterial'. These disease characteristics are also reflected in the number and nature of concomitant medications, with 84.8% of patients taking ≥5 other medications (in addition to their anti-diabetic treatment), 95.2% receiving anti-hypertensive medications and 64.8% being treated with lipid-lowering agents. The demographic and clinical characteristics were overall comparable between the vildagliptin and placebo groups.Table 1Patient demographic and clinical characteristics (randomized population)Mean ± s.d. or *n* (%)Vildagliptin 50 mg qdPlacebo*n*5055Mean age (years)78.0 ± 2.578.3 ± 2.7Sex Male26 (52.0)30 (54.5) Female24 (48.0)25 (45.5)Race White44 (88.0)43 (78.2) Asian3 (6.0)5 (9.1) Hispanic/latino3 (6.0)6 (10.9) All other0 (0.0)1 (1.8)Mean HbA~1c~ (%)7.8 ± 1.07.9 ± 0.8Mean FPG (mmol/L)8.8 ± 3.28.2 ± 3.1Mean weight (kg)81.2 ± 13.879.9 ± 13.9Mean BMI (kg/m^2^)31.0 ± 4.530.0 ± 4.4Mean duration of T2DM (years)14.0 ± 9.718.1 ± 10.0 Disease duration group (years)  ≥543 (86.0)47 (85.5)  ≥1029 (58.0)41 (74.5)Mean eGFR (MDRD) (ml/min/1.73 m^2^)35.5 ± 9.435.1 ± 9.5 eGFR group  Moderate (≥30 to \<50)36 (72.0)35 (63.6)  Severe (\<30)14 (28.0)20 (36.4)Previous antidiabetic medication \[*n* (%)\] Drug-naive4 (8.0)1 (1.8) Insulin monotherapy26 (52.0)32 (58.2) Insulin and OAD3 (6.0)11 (20.0) OAD monotherapy17 (34.0)9 (16.4) OAD combination therapy0 (0.0)2 (3.6)CV history Hypertension48 (96.0)53 (96.4) Dyslipidemia36 (72.0)36 (65.5) High CV risk status^a^26 (52.0)30 (54.5)Concomitant medications at BL (in addition to any anti-diabetic medications) ≥5 Medications42 (84.0)47 (85.5) Anti-hypertensive medications47 (94.0)53 (96.4) Lipid-lowering medications34 (68.0)34 (61.8)*BL* baseline, *BMI* body mass index, *CV* cardiovascular, *FPG* fasting plasma glucose, *GFR* glomerular filtration rate, *HbA* ~*1c*~ glycated hemoglobin, *MDRD* modification of diet in renal disease, *OAD* oral anti-diabetic drug, *s.d*. standard deviation, *SMQ* standardized MedDRA query, *SU* sulfonylurea, *T2DM* type 2 diabetes^a^High CV risk status includes patients with a previous history of CV and cerebrovascular events in the SMQs of "ischemic heart disease, cardiac failure, ischemic cerebrovascular conditions and/or embolic thrombotic events, arterial"

Efficacy {#Sec9}
========

In the patients ≥75 years with T2DM and moderate/severe RI receiving vildagliptin 50 mg qd added to background therapy, the AM∆ in HbA~1c~ from baseline (7.8% ± 0.2%) to week 24 endpoint was −1.0% ± 0.2%, while in the patients receiving placebo added to background therapy the AM∆ from baseline (7.9% ± 0.1%) to endpoint was −0.2% ± 0.2% (Fig. [1](#Fig1){ref-type="fig"}a). This resulted in a significant between-group difference (vildagliptin--placebo) of −0.8% ± 0.2% (*p* \< 0.001). The percentage of vildagliptin-treated patients (with baseline HbA~1c~ \>7.5%) achieving endpoint HbA~1c~ ≤7.5%, a target consistent with the vulnerable patient population \[[@CR3], [@CR21], [@CR22]\], was nearly twice that reported in the placebo group (51.9% vs. 26.3%).Fig. 1**a** Adjusted mean (±SEM) change from baseline to week 24 endpoint in HbA~1c~ in patients adding vildagliptin 50 mg qd (*n* = 49) or placebo (*n* = 55) to their ongoing background therapy; ∗*p* \< 0.001 (between-group difference). An ANCOVA model with baseline value, background therapy, pooled center and treatment as covariates was used. **b** Events per patient-year of hypoglycemia during 24-week treatment with vildagliptin 50 mg qd (*n* = 50) or placebo (*n* = 55) added to their ongoing background therapy; *p* = 0.970 (between-group difference). *BL* baseline

FPG also decreased with vildagliptin. The AM∆ in FPG in the vildagliptin group was −1.1 ± 0.6 mmol/L (baseline 8.9 ± 0.5 mmol/L); however, the between-treatment difference (−0.9 ± 0.5 mmol/L) did not achieve statistical significance (*p* = 0.088).

Body weight remained stable in the vildagliptin group; baseline weight averaged 81.1 ± 2.0 kg and the AM∆ was 0.4 ± 0.7 kg. In the placebo group, the AM∆ was −1.0 ± 0.7 kg from a baseline of 79.8 ± 1.9 kg (*p* = 0.015 vs. vildagliptin).

The markedly lower glucose level achieved with vildagliptin vs. placebo added to background therapy was not associated with an increased risk of hypoglycemia. Figure [1](#Fig1){ref-type="fig"}b shows the frequency of confirmed hypoglycemia over 24 weeks of treatment. The rate of hypoglycemia was 0.49 events per patient-year with vildagliptin and 0.96 events per patient-year with placebo (not significant; *p* = 0.970). Expressed in absolute number of events, in the vildagliptin group 5 patients reported a total of 11 events, while in the placebo group 4 patients reported a total of 23 events. Furthermore, severe hypoglycemia (i.e. requiring assistance of another party) was rare in both treatment groups (experienced by 1 patient in the vildagliptin group and 0 patients in the placebo group), and no patients in either treatment group discontinued due to hypoglycemia.

Safety and Tolerability {#Sec10}
-----------------------

The overall AE profile was similar in elderly patients with moderate/severe RI receiving vildagliptin or placebo (Table [2](#Tab2){ref-type="table"}).Table 2Adverse events (safety set)Vildagliptin 50 mg qd, *n* (%)Placebo, *n* (%)*n*5055AEs29 (58.0)40 (72.7)SAEs7 (14.0)9 (16.4)Discontinuation due to AEs2 (4.0)5 (9.1)Deaths0 (0.0)3 (5.5)AEs in SOCs Cardiac disorders2 (4.0)10 (18.2) Gastrointestinal disorders4 (8.0)11 (20.0) Infections and infestations14 (28.0)11 (20.0) Musculoskeletal and connective tissue disorders8 (16.0)9 (16.4) Nervous system disorders9 (18.0)15 (27.3) Skin and subcutaneous tissue disorders5 (10.0)8 (14.5)Most common AEs by preferred term^a^ Edema6 (12.0)9 (16.4) Nasopharyngitis6 (12.0)4 (7.3) Dizziness2 (4.0)8 (14.5) Fatigue3 (6.0)3 (5.5) Hyperhidrosis1 (2.0)5 (9.1)*AE* adverse event, *n* number of patients with an AE, *SAE* serious adverse event, *SOC* system organ class^a^≥10% in the study

Adverse events (58.0% vs. 72.7%) and discontinuations due to AEs (4.0% vs. 9.1%) were reported with a somewhat lower frequency in elderly patients with moderate/severe RI receiving vildagliptin than in patients receiving placebo, and the incidence of serious AEs (SAEs) was similar in the two treatment groups (14.0% vs. 16.4%) (Table [2](#Tab2){ref-type="table"}). No patient in the vildagliptin treatment group died, while 3 patients (5.5%) died in the placebo group (1 myocardial infarction, 1 cardiogenic shock, and 1 upper gastrointestinal hemorrhage) (Table [2](#Tab2){ref-type="table"}).

When system organ classes (SOCs) of interest in this elderly patient population with moderate/severe RI were analyzed (Table [2](#Tab2){ref-type="table"}), lower incidences of AEs were reported with vildagliptin vs. placebo in the SOCs of cardiac disorders (4.0% vs. 18.2%; the difference not being driven by a particular type of event) and gastrointestinal disorders (8.0% vs. 20.0%; with the largest difference seen for diarrhea). The AE rates in the SOCs of infections and infestations, musculoskeletal and connective tissue disorders, nervous system disorders and skin and subcutaneous tissue disorders were overall similar between vildagliptin and placebo. As further detailed in Table [2](#Tab2){ref-type="table"}, the most commonly reported specific AEs were edema (12.0% with vildagliptin vs. 16.4% with placebo), nasopharyngitis (12.0% vs. 7.3%) and dizziness (4.0% vs. 14.5%). Most of the AEs in both treatment groups were mild or moderate, with only 8.0% of patients in the vildagliptin group and 12.7% of patients in the placebo group experiencing severe events.

There was no deterioration of renal function with vildagliptin after 24 weeks of treatment as assessed by the eGFR (change from baseline −0.1 vs. −2.0 ml/min/1.73 m^2^ with placebo).

Discussion {#Sec11}
==========

The present sub-analysis evaluated vildagliptin in the uniquely vulnerable elderly population ≥75 years with T2DM and moderate or severe RI, many of whom (nearly 70%) were treated with insulin. The main finding was that vildagliptin was efficacious, with no increase in the rate of hypoglycemia compared to placebo despite a marked improvement in glycemic control.

The magnitude of the glucose-lowering seen in this subgroup (HbA~1c~ reduction of −1.0% from a baseline of 7.8%) was similar to that seen previously in patients ≥75 years with mostly normal renal function or mild RI receiving vildagliptin monotherapy or add-on therapy to metformin (−0.9% to −1.1%) \[[@CR16]\] or in a population with severe RI with a mean age of 64 years receiving background insulin therapy (−0.9%) \[[@CR18]\], which was also reported to be consistent with that seen for vildagliptin in the general population in monotherapy or combination therapy studies. Relative to placebo, the decrease in HbA~1c~ (−0.8%) was clinically meaningful, with more than half of the vildagliptin-treated patients reaching an HbA~1c~ ≤7.5%, regarded an appropriate target for this patient population \[[@CR3], [@CR21], [@CR22]\]. Thus, the metabolic derangements clearly manifested in this patient population with advanced age, RI, and long-standing mainly insulin-treated T2DM \[[@CR23]\] did not adversely affect the efficacy of vildagliptin. The small HbA~1c~ reduction (−0.2%) seen in the control group is likely a study effect and not unusual for patients entering a placebo-controlled trial.

Hypoglycemia is a major limiting barrier to good glycemic control even in the general population \[[@CR15]\]. In light of the markedly increased risk of hypoglycemia, including severe hypoglycemia, in a highly vulnerable patient population of advanced age, with RI and significant insulin use \[[@CR2], [@CR8]--[@CR12]\] and given the more severe consequences of hypoglycemia in these patients (including events like falls and fractures \[[@CR2]\]), as well as the potential CV risk associated with severe hypoglycemia \[[@CR2], [@CR24]\], the finding that there was no increase in the rate of hypoglycemia with vildagliptin despite the meaningful decrease in mean HbA~1c~ (7.8% to 6.8%) is noteworthy. The rate of confirmed hypoglycemia was 0.49 vs. 0.96 events per patient-year with vildagliptin and placebo, respectively, with a very low incidence of severe hypoglycemia (1 patient on multiple insulin injections in the vildagliptin group, precipitated by alcohol consumption, and 0 patients in the placebo group) and no discontinuations due to hypoglycemia. While an improvement in glycemic control in the range reported in the current analysis would generally be expected to be associated with an increase in hypoglycemia, in particular, in the patient population studied, the protection against hypoglycemia seen with vildagliptin has a mechanistic basis, likely being mediated via a GIP-induced increase in glucagon levels whenever glucose levels fall into the hypoglycemic range \[[@CR14], [@CR20]\]. Vildagliptin treatment extends the physiological meal-related increases of the incretin hormones into the inter-meal and overnight periods and vildagliptin was shown to enhance the glucagon counter-regulatory response to hypoglycemia during a stepped clamp versus placebo in drug-naïve patients with T2DM \[[@CR14], [@CR25]\].

Consistent with the weight neutrality generally reported for vildagliptin \[[@CR26]\] including in insulin-treated patients \[[@CR20]\], there was only a minimal weight change (0.4 kg) reported for vildagliptin when added to background therapy in the elderly patient group with moderate/severe RI.

The safety and tolerability of vildagliptin in a wide range of disease stages including pooled analyses from a large clinical database was assessed in detail previously \[[@CR16], [@CR17], [@CR20], [@CR27]--[@CR29]\]. The results from the present investigation are consistent with the safety and tolerability profile reported earlier, with no new safety signals identified in the present sub-analysis. While a numerically lower percentage of vildagliptin-treated patients experienced events in the SOC of Cardiac disorders (4% vs. 18.2%), a trend similar to that seen in an earlier pooled analysis of elderly patients ≥75 years \[[@CR16]\], this was not driven by any particular type of events and based on a very small number of events, thus limiting definitive conclusions.

In light of the broader applicability of the reported results, while inclusion/exclusion criteria in clinical trials can restrict the demographic and disease characteristics compared to a real life setting, the patients studied in the present analysis were overall reflective of an elderly patient population with advanced renal insufficiency, thus further extending the findings of a previously pooled analysis of a patient population ≥75 years with mainly normal renal function or mild RI \[[@CR16]\] and of a study in a population ≥70 years including a small percentage of patients with moderate RI (14.4%) but no patients with severe RI \[[@CR30]\]. The latter study showed that nearly twice as many patients reached individualized treatment targets with vildagliptin than placebo added to their background therapy, with comparable safety and tolerability. In the present sub-analysis, nearly 1/3 of patients ≥75 years had severe RI and the remaining about 2/3 of patients had moderate RI, with a mean eGFR of 35 ml/min/1.73 m^2^. In addition to the renal comorbidity, patients also had a high prevalence of CV risk factors \[including obesity (mean BMI 30.5 kg/m^2^), long-standing T2DM (mean duration of 16.2 years, with 2/3 of patients being diagnosed for ≥10 years), hypertension (\>90%), dyslipidemia (\>2/3)\], and \>50% had a high CV risk status based on previous CCV history. These factors, together with the fact that \~70% of patients were treated with insulin and \~85% of patients taking ≥5 other medications (in addition to their anti-diabetic treatment), highlight the uniquely fragile/vulnerable characteristics of the studied population. It is worth noting, however, that while the mean age of the population was 78.1 years, the upper age of the patients was 85 years, thus the data cannot necessarily be extrapolated to a population of \>85 years. Another limitation of the present investigation is that the results are based on a sizeable yet limited number of patients. Furthermore, information that would have allowed to characterize the population with respect to dependency (e.g. care home residency) or mental status is lacking.

Conclusion {#Sec12}
==========

Taken together, the present sub-study provides valuable information regarding the experience with vildagliptin in the difficult-to-treat elderly population ≥75 years with T2DM and moderate or severe RI.
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